Publication Name	World Journal of Gastroenterology
Manuscript ID	65865
Country	Japan

Received	2021-03-17 02:52
Peer-Review Started	2021-03-17 03:15
To Make the First Decision
Return for Revision	2021-04-17 04:54
Revised	2021-04-23 08:26
Second Decision	2021-05-07 13:38
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2021-05-07 14:11
Articles in Press	2021-05-07 14:11
Publication Fee Transferred
Edit the Manuscript by Language Editor	2021-05-13 19:40
Typeset the Manuscript	2021-06-04 11:18
Publish the Manuscript Online	2021-06-18 05:06

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Minireviews
Article Title	Can control of gut microbiota be a future therapeutic option for inflammatory bowel disease?
Manuscript Source	Invited Manuscript
All Author List	Atsushi Nishida, Kyohei Nishino, Keitaro Sakai, Yuji Owaki, Yoshika Noda and Hirotsugu Imaeda
ORCID	Author(s) ORCID Number Atsushi Nishida http://orcid.org/0000-0002-1288-3272 Kyohei Nishino http://orcid.org/0000-0001-9798-6731 Keitaro Sakai http://orcid.org/0000-0001-8131-6717 Yuji Owaki http://orcid.org/0000-0001-7932-5016 Yoshika Noda http://orcid.org/0000-0003-2358-0565 Hirotsugu Imaeda http://orcid.org/0000-0002-5516-8527
Funding Agency and Grant Number
Corresponding Author	Atsushi Nishida, MD, PhD, Chief Doctor, Department of Gastroenterology and Hepatology, Nagahama City Hospital, 313 Oinuicho, Nagahama 5268580, Shiga, Japan. atsuda@belle.shiga-med.ac.jp
Key Words	Inflammatory bowel disease; Dysbiosis; Fecal microbiota transplantation; Short chain fatty acid; Probiotics
Core Tip	In this review, we discuss the gut microbiota in inflammatory bowel disease (IBD) and gut microbiota-derived metabolites, especially short chain fatty acids (SCFAs). The anti-inflammatory function of SCFAs on the mucosal immune system in the gastrointestinal tract is also discussed. In addition, we review the efficacy of probiotics on IBD and the current clinical trials on the effectiveness of fecal microbiota transplantation on IBD.
Publish Date	2021-06-18 05:06
Citation	Nishida A, Nishino K, Sakai K, Owaki Y, Noda Y, Imaeda H. Can control of gut microbiota be a future therapeutic option for inflammatory bowel disease? World J Gastroenterol 2021; 27(23): 3317-3326
URL	https://www.wjgnet.com/1007-9327/full/v27/i23/3317.htm
DOI	https://dx.doi.org/10.3748/wjg.v27.i23.3317

Full Article (PDF)	WJG-27-3317.pdf
Full Article (Word)	WJG-27-3317.docx
Manuscript File	65865-Review-FilipodiaCL.docx
Answering Reviewers	65865-Answering reviewers.pdf
Audio Core Tip	65865-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	65865-Conflict-of-interest statement.pdf
Copyright License Agreement	65865-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	65865-Language certificate.pdf
Peer-review Report	65865-Peer-review(s).pdf
Scientific Misconduct Check	65865-Bing-Liu M-1.png
Scientific Misconduct Check	65865-Scientific misconduct check.pdf
Scientific Editor Work List	65865-Scientific editor work list.pdf